Combination Inhaled Therapy in COPD: The Impact of Recent Data

Slides:

Advertisements

Similar presentations

Delphine Sculier, MD,MPH Stop TB Department World Health Organisation Geneva, Switzerland Update on the revision of ART guidelines for TB patients.

Advertisements

Pulmonary and Allergy Drugs Advisory Committee January 17, 2002 Pulmonary and Allergy Drugs Advisory Committee Meeting Gaithersburg, Maryland January 17,

LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,

내과 R2 이지훈 N Engl J Med Sep 8.

(22%) (15%) (10%) (9%) (40%) (< 10% )

1 Once-daily indacaterol versus twice-daily salmeterol for COPD ; a placebo-controlled comparison R2 정명화 Eur Respir J 2011; 37: 273–279.

내과 R2 이지영. INTRODUCTION  Asthma  Allergic airway inflammation,Th2-weighted process  Biomarkers  Phenotypic distinctions  Development of personalized.

GOLD 2017 major revision: Summary of key changes

Respiratory Initiatives: GOLD - ABCD, CAT Scores and myCOPD

Upfront Combination Therapy vs Step-Up Approach for PAH:

COPD Report 5 Coles Lane, Oakington, Cambridge, CB24 3BA.

Blood eosinophil count and exacerbation risk in patients with COPD

Practical Recommendations for COPD:

COPD by the Guidelines.

Treatment Strategies in Mild to Moderate COPD

RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL

A Paradigm Shift in PAH.

COPD Management.

Stepping Up Asthma Control for Effective Management

Managing Complex Hypertension: What Every Physician Should Know

Dual Bronchodilation in COPD: From Clinical Trial Evidence to Clinical Practice.

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

What Is the Role of Dual LAMA/LABA Bronchodilation in COPD Therapy in Light of New Clinical Data?

Volume 153, Issue 4, Pages (April 2018)

Volume 153, Issue 4, Pages (April 2018)

All About PAH:.

An Interprofessional Approach to the Patient With Chronic Airway Disease.

Early Type 2 Diabetes Mellitus: A Cardiovascular Disease

Blood pressure control: dependence on adherence

When Would You Use Single Inhaler Triple Therapy in COPD?

Treating Vasodilatory Shock in the ICU

Blood eosinophils as a marker of eosinophilic exacerbations in COPD

HCV Protease Inhibitors in Clinical Practice

Cardiovascular Comorbidities A Common Occurrence With COPD

Precision Medicine Urgency

Program Goals. Treatment-Naive Patients With PAH What Do We Know and What Choices Do We Have?

How to Optimize TAVR Outcomes

Targeting Osteoporosis Therapies to Patients at Highest Risk for Fracture.

Therapeutic Strategies in COPD Focus on Patient Characteristics and Drug Delivery.

Translating the Latest and Greatest Advances in PAH Into Clinical Practice.

Managing Polycythemia Vera in the Community Setting

Volume 152, Issue 6, Pages (December 2017)

Maintenance Therapy in Advanced Ovarian Cancer

What's New in Therapeutic Options for Moderate to Severe RA?

PAH and Prostacyclin Pathways in Focus

Long-Acting Agents in Severe COPD

HCV Protease Inhibitors in Clinical Practice

Personalizing COPD Therapy According to Recent Clinical Trial Evidence

The Adherence Challenge in Schizophrenia Roles of Current and Emerging Therapies.

LDL Cholesterol.

Diagnosis, Evaluation, and Therapy for Severe Refractory Eosinophilic Asthma.

Communicating With Your Patients About Major Depressive Disorder

Incorporating Prostacyclins Into Practice

The Rising Crisis of Prediabetes Diagnosis and Management of the Patient With Prediabetes.

Improving Adherence to Antiplatelet Therapy After an ACS Event

Inhaled Antibiotics for Patients With CF in the Era of CFTR Modulators

Disease Burden of VTE Phases of VTE Treatment.

Peripheral blood eosinophil levels based on a threshold of (A) 150 cells/μL, patients not randomised to inhaled corticosteroids (ICS)-containing treatment.

Strategies for Infection Control in Cystic Fibrosis

Pinja Ilmarinen, PhD, Leena E

Schematic overview of the suggested pharmacological management of chronic obstructive pulmonary disease (COPD). Schematic overview of the suggested pharmacological.

Pulmonary Arterial Hypertension and Hospitalizations

Practical Recommendations for COPD:

Targeted Care for COPD.

Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification based on symptom and risk evaluation. a) GOLD model of symptom/risk evaluation.

Exploring the Role of Biologics in Reducing Oral Corticosteroid Use in Severe Asthma.

Agenda. Diagnosis, Assessment, and Treatment of the COPD Patient in Primary Care.

Khai Hoan Tram, Jane O’Halloran, Rachel Presti, Jeffrey Atkinson

Presentation transcript:

Combination Inhaled Therapy in COPD: The Impact of Recent Data

Treatment Goals for Stable COPD Management

Major Long-Term Impact of Exacerbations

Major Long-Term Impact of Severity of COPD

Predictors of Mortality: Multivariate Analysis

History of Exacerbations and Risk of Recurrence

Available Medications

Therapeutic Recommendations

FLAME STUDY: Effect of IND/GLY on Time to First Exacerbation Compared With SFC

IMPACT

Individualized Benefit-Risk Assessment

Blood Eosinophils and Prediction of Risk of Exacerbation

Improving Adherence Saves Costs

Conclusion

Key Studies With Triple Inhaler Therapy

Key Studies With Triple Inhaler Therapy

LABA/LAMA/ICS vs LABA/ICS: FULFIL Design

FULFIL: Inclusion Criteria

Change of FEV1 at 24 Weeks

Change of FEV1 at 52 Weeks

Effect on SGRQ Score

Effect on SGRQ Score (Cont.)

LABA/LAMA/ICS vs LABA/ICS: TRILOGY

TRILOGY: Inclusion Criteria

Effects on FEV1 and TDI Score

Evolution of Exacerbations

LABA/LAMA/ICS vs LABA/LAMA: TRIBUTE

TRIBUTE: Inclusion Criteria

Effect on Exacerbations

Effect on FEV1

Effect on SGRQ Score

TRIBUTE: Main Adverse Events

LABA/LAMA/ICS vs LABA/ICS and LABA/LAMA: IMPACT

IMPACT: Inclusion Criteria

Evolution of Exacerbations

Effect on FEV1 and SGRQ Score

IMPACT: Results on Mortality

IMPACT: Incidence of Pneumonia

Conclusion

From Recent Studies to Individualization of Treatment: When to Use a Single Inhaled Triple Therapy in COPD

TRIBUTE: Effect on Exacerbations

TRIBUTE: Inclusion Criteria

IMPACT: Effect on Exacerbations

IMPACT: Inclusion Criteria

FLAME Study

IMPACT: Inclusion Criteria

IMPACT: Results on Mortality

IMPACT: Incidence of Pneumonia

Factors Associated With the Risk of Pneumonia in Patients Taking ICS

IMPACT: Incidence of Pneumonia

Rate of Moderate/Severe Exacerbations With FF/UMEC/VI in Patients With Blood Eosinophil Count < 150 and ≥ 150 Cells/μL

Blood Eosinophils and Prediction of Risk of Exacerbation

ICS Response Depends on Eosinophils level

Conclusion

Abbreviations

Abbreviations (cont)